The Movement Disorder Division is focused on the discovery of new drugs for better management of symptoms of Parkinson’s disease and other movement disorders. Research studies are both multi-center (national and international) or single center conducted at Yale University. All human studies are approved by the Yale Human Investigation Committee. The Movement Disorder Division also conducts research studies on the efficacy and safety of botulinum toxins in movement disorders and pain. Other research protocols pertain to the study of different symptoms in Parkinson’s disease and the application of modern neuroimaging such as fMRI and MR spectroscopy in order to discern the pathophysiology of movement disorders. The movement disorder specialists also collaborate with researchers in the Institute of Neurodegenerative Disorders (60 Temple St) and refer patients for research studies in that Institute.